Ilyas M, Efstathiou J A, Straub J, Kim H C, Bodmer W F
Cancer and Immunogenetics Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom.
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3087-91. doi: 10.1073/pnas.96.6.3087.
The type II transforming growth factor (TGF)-beta receptor gene (TGFBR2) is often mutated in nucleotide repeat sequences in colorectal cancers that are replication error positive (RER+). These mutations are thought to be selected for escape from growth inhibition by TGF-beta rather than representing bystander events because of an increased mutation rate. We investigated the role of TGFBR2 mutations in 12 colorectal cancer cell lines. Six of these were RER+, and these were shown to have homozygous TGFBR2 mutations. All cell lines then were tested for changes in proliferation in response to TGF-beta stimulation. Despite homozygous mutation of the type II TGF-beta receptor, two RER+ cell lines, Lovo and SW48, showed statistically significant growth inhibition when stimulated by TGF-beta1 in serum-free conditions. This shows that the type II TGF-beta receptor can be bypassed in certain cases to maintain growth inhibition. We next investigated whether there was any alternative mode through which TGFBR2 mutation may give a selective advantage, such as a change in adhesion molecule expression. All cell lines were stimulated with TGF-beta1 and adhesion molecules detected by ELISA. No consistent changes were identified between the RER+ and the RER- cell lines, although changes in E-cadherin, beta-catenin, and gamma-catenin were identified in individual cell lines. We conclude that (i) type II TGF-beta receptor activity can be bypassed and thus TGFBR2 mutations in RER+ cancers may, at least sometimes, be just "bystander" events and (ii) TGF-beta can affect adhesion molecule expression so that TGFBR2 mutation may give rise to a selective advantage through an effect other escape from growth inhibition.
II型转化生长因子(TGF)-β受体基因(TGFBR2)在复制错误阳性(RER+)的结直肠癌核苷酸重复序列中常发生突变。这些突变被认为是为了逃避TGF-β的生长抑制作用而被选择出来的,而非由于突变率增加导致的旁观者效应。我们研究了TGFBR2突变在12种结直肠癌细胞系中的作用。其中6种为RER+,且这些细胞系显示存在TGFBR2纯合突变。随后对所有细胞系进行检测,观察其在TGF-β刺激下增殖的变化。尽管II型TGF-β受体发生了纯合突变,但在无血清条件下,两种RER+细胞系Lovo和SW48在受到TGF-β1刺激时,仍表现出统计学上显著的生长抑制。这表明在某些情况下,可以绕过II型TGF-β受体来维持生长抑制。接下来,我们研究TGFBR2突变是否可能通过其他替代模式赋予选择性优势,例如黏附分子表达的改变。用TGF-β1刺激所有细胞系,并用酶联免疫吸附测定法检测黏附分子。尽管在个别细胞系中发现了E-钙黏蛋白、β-连环蛋白和γ-连环蛋白的变化,但RER+和RER-细胞系之间未发现一致的变化。我们得出结论:(i)II型TGF-β受体活性可以被绕过,因此RER+癌症中的TGFBR2突变至少在某些时候可能只是“旁观者”事件;(ii)TGF-β可以影响黏附分子表达,从而使TGFBR2突变可能通过除逃避生长抑制之外的其他效应产生选择性优势。